ZK 807834

Known as: ZK-807834 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The ex vivo testing emerges as an essential and critical step for the selection of the most promising prospective anticoagulant… (More)
Is this relevant?
2007
2007
It was the objective of this study to evaluate the anti-thrombotic potency of direct factor-Xa inhibition with ZK-807834 in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2003
2003
Inhibition of factor Xa with the small molecule inhibitor ZK-807834 (Mr 527 Da, Ki 0.11 nM) attenuates progression of thrombosis… (More)
Is this relevant?
Review
2002
Review
2002
Berlex (a Schering subsidiary) and Pfizer (formerly Parke-Davis) are developing ZK-807834 (CI-1031), one of a series of Factor Xa… (More)
Is this relevant?
2002
2002
ZK-807834 (also known as CI-1031) is a small molecule that potently and selectively inhibits Factor Xa. Studies in animals have… (More)
Is this relevant?
2002
2002
CI-1031 (ZK-807834) is a novel, synthetic factor Xa (FXa) inhibitor with a Ki of 0.11 nM against human FXa. In human plasma in… (More)
Is this relevant?
2001
2001
During thrombosis, vascular wall cells are exposed to clotting factors, including the procoagulant proteases thrombin and factor… (More)
Is this relevant?
2001
2001
Factor Xa is a serine protease positioned at the convergence point of the intrinsic and extrinsic coagulation pathways and is… (More)
Is this relevant?
2000
2000
Factor Xa plays a critical role in the formation of blood clots. This serine protease catalyzes the conversion of prothrombin to… (More)
Is this relevant?
2000
2000
Inhibition of factor Xa (FXa) may interrupt thrombus progression. This study compared the antithrombotic activity of a novel FXa… (More)
Is this relevant?